Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Minerva Neurosciences (NERV)
NASDAQ:NERV
RESEARCH TOOLSreports
Holding NERV?
Track your performance easily
NERV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.26 - $13.49
Previous Close$2.93
Volume9.73K
Average Volume (3M)20.40K
Market Cap
$20.46M
Enterprise Value-$10.43M
Total Cash (Recent Filing)$30.88M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Nov 04, 2024EPS Estimate
-$1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.45
Shares Outstanding6,993,406
10 Day Avg. Volume12,158
30 Day Avg. Volume20,402
Standard Deviation0.53
R-Squared0.00016
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)-0.46
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.50
Forecast
1Y Price Target
$5.00Price Target Upside71.82% Upside
Rating ConsensusHold
Number of Analyst Covering1
Minerva Neurosciences News
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentNo new safety signals were observed in the recent Phase 1b clinical trial of roluperidone.
Financial StabilityThe company's cash reserves are expected to sufficiently fund its planned operations, ensuring financial stability for the near future.
InvestmentBoehringer Ingelheim's 18% stake in the company serves as a strong endorsement of roluperidone’s commercial potential.
Bears Say
Drug Efficacy ConcernsThe FDA's concerns about the lack of substantial evidence of a clinically meaningful benefit of roluperidone may lead to skepticism regarding its potential market success.
Financial ConstraintsMinerva's financial constraints could be exacerbated by the need to fund further studies for roluperidone, impacting the company's cash flow and investor confidence.
Regulatory ChallengesThe FDA's requirement for Minerva to conduct additional studies to demonstrate the safety and effectiveness of roluperidone casts doubt on the drug's approval timeline.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NERV FAQ
What was Minerva Neurosciences’s price range in the past 12 months?
Minerva Neurosciences lowest stock price was $2.26 and its highest was $13.49 in the past 12 months.
What is Minerva Neurosciences’s market cap?
Currently, no data Available
When is Minerva Neurosciences’s upcoming earnings report date?
Minerva Neurosciences’s upcoming earnings report date is Nov 04, 2024 which is in 45 days.
How were Minerva Neurosciences’s earnings last quarter?
Minerva Neurosciences released its earnings results on Aug 06, 2024. The company reported -$1.09 earnings per share for the quarter, missing the consensus estimate of -$0.97 by -$0.12.
Is Minerva Neurosciences overvalued?
According to Wall Street analysts Minerva Neurosciences’s price is currently Undervalued.
Does Minerva Neurosciences pay dividends?
Minerva Neurosciences does not currently pay dividends.
What is Minerva Neurosciences’s EPS estimate?
Minerva Neurosciences’s EPS estimate is -$1.01.
How many shares outstanding does Minerva Neurosciences have?
Minerva Neurosciences has 6,993,406 shares outstanding.
What happened to Minerva Neurosciences’s price movement after its last earnings report?
Minerva Neurosciences reported an EPS of -$1.09 in its last earnings report, missing expectations of -$0.97. Following the earnings report the stock price went up 5%.
Which hedge fund is a major shareholder of Minerva Neurosciences?
Currently, no hedge funds are holding shares in NERV
---
Minerva Neurosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.00 (71.82% Upside)
$5.00 (71.82% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.05%
Trailing 12-Months
Company Description
Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. Its product pipeline includes Roluperidone, Seltorexant, MIN-117, and MIN-301. The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Cambridge, MA.
---
NERV Earnings Call
Q1 2023
0:00 / 0:00
---
NERV Stock 12 Month Forecast
Average Price Target
$5.00
▲(71.82% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
SAGE Therapeutics
―
Axsome Therapeutics
―
Viking Therapeutics
―
---